<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="52627"><DrugName>transferrin modulating apoptosis inducers (cancer), EpiCept</DrugName><DrugSynonyms><Name><Value>MX-2167</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>transferrin modulating apoptosis inducers (cancer), Maxim</Value></Name><Name><Value>transferrin modulating apoptosis inducers (cancer), EpiCept</Value></Name><Name><Value>EP-2167</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23065">Maxim Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="23065">Maxim Pharmaceuticals Inc</Company><Company id="27183">EpiCept Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="52627" type="Drug"><TargetEntity id="335920" type="siDrug">MX-2167</TargetEntity></SourceEntity><SourceEntity id="23065" type="Company"><TargetEntity id="4295907086" type="organizationId">Maxim Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="1515">Transferrin modulator</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="1589">Apoptosis stimulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-29T08:54:57.000Z</LastModificationDate><ChangeDateLast>2009-04-15T11:51:36.000Z</ChangeDateLast><AddedDate>2004-12-30T16:24:29.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="27183" linkType="Company"&gt;EpiCept&lt;/ulink&gt;, following the merger between EpiCept and &lt;ulink linkID="23065" linkType="Company"&gt;Maxim Pharmaceuticals&lt;/ulink&gt; [&lt;ulink linkID="643513" linkType="Reference"&gt;643513&lt;/ulink&gt;], was investigating cell-surface transferrin receptor modulators, including  EP-2167 (presumed to be MX-2167) as apoptosis inducers for the potential treatment of cancer [&lt;ulink linkID="972475" linkType="Reference"&gt;972475&lt;/ulink&gt;]. In July 2003, EP-2167 was expected to enter the clinic in the second half of 2004 [&lt;ulink linkID="496768" linkType="Reference"&gt;496768&lt;/ulink&gt;]; however, by December 2008, the program was still in preclinical development [&lt;ulink linkID="972475" linkType="Reference"&gt;972475&lt;/ulink&gt;]. In January 2009, EpiCept terminated all drug discovery activities and development of the series was presumed to be discontinued [&lt;ulink linkID="975862" linkType="Reference"&gt;975862&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2004, preclinical data on EP-2167 were presented at the 16th EORTC-NCI-AACR meeting in Geneva, Switzerland. In  rats, a dose of 5 mg/kg had a half-life of 9.9 h and the plasma drug concentration after 24 h was above the EC50 value. At an intravenous dose of 30 mg/kg,  EP-2167 was  found to be safe, with monocytes, eosinophils, basophils and platelet counts within the normal range. The change in lymphocyte and neutrophil counts on day 2 normalized by day 14 [&lt;ulink linkID="563120" linkType="Reference"&gt;563120&lt;/ulink&gt;], [&lt;ulink linkID="562086" linkType="Reference"&gt;562086&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2003, preclinical data on EP-2167 were presented at the 15th AACR-NCI-EORTC meeting in Boston, MA. EP-2167 demonstrated good pharmacokinetic properties and potent efficacy in the rat cell syngeneic prostate cancer model (MatLy Lu), with 90% inhibition of tumor growth and moderate dosing schedules. It induced apoptosis with a broad spectrum of activity by acting from outside the cell and was efficacious in both syngeneic and xenograft tumor models [&lt;ulink linkID="514570" linkType="Reference"&gt;514570&lt;/ulink&gt;].  Although not presented at the meeting, limited preclinical data on another apoptosis stimulator, MX-90745 and its analogs were also included in the associated abstract book. Selected analogs were examined in the MX1 human breast cancer xenograft model in nude mice and significant tumor growth reduction of over 90% was observed with single doses [&lt;ulink linkID="514560" linkType="Reference"&gt;514560&lt;/ulink&gt;]. Similar data were presented in September 2004 at the 16th EORTC-NCI-AACR meeting in Geneva, Switzerland [&lt;ulink linkID="563120" linkType="Reference"&gt;563120&lt;/ulink&gt;], [&lt;ulink linkID="562086" linkType="Reference"&gt;562086&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, preclinical data on EP-2167 were presented at the 94th AACR meeting in Washington, DC. In a breast cancer (MX-1) xenograft murine model efficacy study, a cremophor formulation of EP-2167 given once daily by intravenous injection at dose of 100 mg/kg/day for 5 days resulted in almost 70% tumor shrinkage, while in a prostate cancer (Mat LyLu) Dunning rat model, an improved formulation administered iv at a dose of 40 mg/kg on days 1 and 5, and 30 mg/kg on day 3, for 2 weeks resulted in 89% tumor shrinkage. Pharmacokinetic studies in Copenhagen rats indicated that EP-2167 has a long terminal half-life and can sustain an effective concentration over a prolonged period, while safety toxicology data generated from the same model suggested minimal drug-related effects on complete blood count, blood chemistry and histopathology of major organs at a dose of 30 mg/kg, once daily for 5 days [&lt;ulink linkID="496768" linkType="reference"&gt;496768&lt;/ulink&gt;]. Similar data were presented in September 2004 at the 16th EORTC-NCI-AACR meeting in Geneva, Switzerland [&lt;ulink linkID="563120" linkType="Reference"&gt;563120&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2003, Maxim published preclinical data on  EP-2167.  It showed significant tumor growth inhibition versus a vehicle control in multiple mouse and rat models for breast and colorectal cancer. In a mouse colorectal model, treatment with EP-2167 produced a dose-dependent reduction in tumor growth [&lt;ulink linkID="486218" linkType="Reference"&gt;486218&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004, preclinical data on EP-2167 were presented at the Sixth SRI Anti-Cancer Drug Discovery and Development Summit in Philadelphia, PA.  The compound induced growth inhibition in cancer cell lines with GI50 values in the range of 65 to 500 nM. EP-2167 was effective in a number of tumor models in mice and rats, including MX-1 (breast), BF16/F10 (melanoma), Mat LyLu (prostate) and LTW (sarcoma) [&lt;ulink linkID="553944" linkType="Reference"&gt;553944&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In April 2003, Maxim filed US patent applications for two novel molecular targets which are involved in the mechanism of action of EP-2167 and MX-126374 [&lt;ulink linkID="486806" linkType="Reference"&gt;486806&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2003, Maxim was awarded from the &lt;ulink linkID="20519" linkType="Company"&gt;NCI&lt;/ulink&gt; a Phase II SBIR grant of $750,000 to fund additional testing of EP-2167 [&lt;ulink linkID="481795" linkType="Reference"&gt;481795&lt;/ulink&gt;].  &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="27183">EpiCept Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-01-12T00:00:00.000Z</StatusDate><Source id="975862" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23065">Maxim Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2003-03-13T00:00:00.000Z</StatusDate><Source id="481795" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27183">EpiCept Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2006-01-04T00:00:00.000Z</StatusDate><Source id="643513" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01882"><Name>Transferrin</Name><SwissprotNumbers><Swissprot>O93429</Swissprot><Swissprot>P02787</Swissprot><Swissprot>P02789</Swissprot><Swissprot>P09571</Swissprot><Swissprot>P12346</Swissprot><Swissprot>P19134</Swissprot><Swissprot>P20233</Swissprot><Swissprot>P27425</Swissprot><Swissprot>P56410</Swissprot><Swissprot>P79815</Swissprot><Swissprot>P79819</Swissprot><Swissprot>Q29443</Swissprot><Swissprot>Q92079</Swissprot><Swissprot>Q921I1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1053945">Immune Pharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="122510" title="NCI to provide funding towards Maxim's EP-2167"></Deal></Deals><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>